Alice Bertaina1, Angela Pitisci2, Matilde Sinibaldi2, Mattia Algeri2. 1. Department of Pediatric Hematology-Oncology, IRCCS, Bambino Gesù Children's Hospital, Piazza Sant'Onofrio, 4 - 00165, Rome, Italy. alice.bertaina@opbg.net. 2. Department of Pediatric Hematology-Oncology, IRCCS, Bambino Gesù Children's Hospital, Piazza Sant'Onofrio, 4 - 00165, Rome, Italy.
Abstract
PURPOSE OF REVIEW: Hematopoietic stem cell transplantation (HSCT) is a treatment option for children with malignant and non-malignant disorders as well as an expanding number of inherited disorders. However, only a limited portion of patients in the need of an allograft have an HLA-compatible, either related or unrelated, donor. Haploidentical HSCT is now considered a valid treatment option, especially in view of the recent insights in terms of graft manipulation. This review will offer an overview of clinical results obtained through the use of haploidentical HSCT in non-malignant diseases. We will analyze major advantages and drawbacks of both T cell depleted and unmanipulated HSCT, discussing future challenges for further improving patients' outcome. RECENT FINDINGS: T cell depletion (TCD) aims to reduce the morbidity and mortality associated with graft-versus-host disease (GvHD). However, the delayed immune recovery and the risk of graft failure still remain potential problems. In the last years, the use of post-transplant cyclophosphamide has been shown to be an alternative effective strategy to prevent GvHD in recipients of haploidentical HSCT. Recent data suggest that both T cell depleted and T cell-replete haplo-HSCT are suitable options to treat children with several types of non-malignant disorders lacking an HLA-identical donor.
PURPOSE OF REVIEW: Hematopoietic stem cell transplantation (HSCT) is a treatment option for children with malignant and non-malignant disorders as well as an expanding number of inherited disorders. However, only a limited portion of patients in the need of an allograft have an HLA-compatible, either related or unrelated, donor. Haploidentical HSCT is now considered a valid treatment option, especially in view of the recent insights in terms of graft manipulation. This review will offer an overview of clinical results obtained through the use of haploidentical HSCT in non-malignant diseases. We will analyze major advantages and drawbacks of both T cell depleted and unmanipulated HSCT, discussing future challenges for further improving patients' outcome. RECENT FINDINGS: T cell depletion (TCD) aims to reduce the morbidity and mortality associated with graft-versus-host disease (GvHD). However, the delayed immune recovery and the risk of graft failure still remain potential problems. In the last years, the use of post-transplant cyclophosphamide has been shown to be an alternative effective strategy to prevent GvHD in recipients of haploidentical HSCT. Recent data suggest that both T cell depleted and T cell-replete haplo-HSCT are suitable options to treat children with several types of non-malignant disorders lacking an HLA-identical donor.
Authors: Juliana F Fernandes; Vanderson Rocha; Myriam Labopin; Benedicte Neven; Despina Moshous; Andrew R Gennery; Wilhelm Friedrich; Fulvio Porta; Cristina Diaz de Heredia; Donna Wall; Yves Bertrand; Paul Veys; Mary Slatter; Ansgar Schulz; Ka Wah Chan; Michael Grimley; Mouhab Ayas; Tayfun Gungor; Wolfram Ebell; Carmem Bonfim; Krzysztof Kalwak; Pierre Taupin; Stéphane Blanche; H Bobby Gaspar; Paul Landais; Alain Fischer; Eliane Gluckman; Marina Cavazzana-Calvo Journal: Blood Date: 2012-02-03 Impact factor: 22.113
Authors: E C Guinan; V A Boussiotis; D Neuberg; L L Brennan; N Hirano; L M Nadler; J G Gribben Journal: N Engl J Med Date: 1999-06-03 Impact factor: 91.245
Authors: I Esteves; C Bonfim; R Pasquini; V Funke; N F Pereira; V Rocha; Y Novis; C Arrais; V Colturato; M P de Souza; M Torres; J F Fernandes; F R Kerbauy; A A F Ribeiro; F P S Santos; N Hamerschlak Journal: Bone Marrow Transplant Date: 2015-03-02 Impact factor: 5.483
Authors: M S Thakar; C Bonfim; B M Sandmaier; P O'Donnell; L Ribeiro; T Gooley; H J Deeg; M E Flowers; R Pasquini; R Storb; A E Woolfrey; H P Kiem Journal: Pediatr Hematol Oncol Date: 2012-07-27 Impact factor: 1.969
Authors: Franco Locatelli; Daniela Pende; Maria C Mingari; Alice Bertaina; Michela Falco; Alessandro Moretta; Lorenzo Moretta Journal: Front Immunol Date: 2013-02-01 Impact factor: 7.561
Authors: Lisa V E Oostenbrink; Emma S Pool; Cornelia M Jol-van der Zijde; Anja M Jansen-Hoogendijk; Carly Vervat; Astrid G S van Halteren; Robbert G M Bredius; Frans J W Smiers; Maarten J D van Tol; Marco W Schilham; Arjan C Lankester; Alexander B Mohseny Journal: Bone Marrow Transplant Date: 2021-05-03 Impact factor: 5.483